Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes.

Acute ischemic stroke, which occurs due to a blockage in cerebral blood flow, requires prompt intervention with thrombolytic ...

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase ...

Disappointment over a cardiology board, an FDA approval, meeting news, and advice for practice—it’s all here this month.

A new clot-busting drug for stroke works as well as a decades-old drug Patients given tenecteplase had similar outcomes to those given alteplase Tenecteplase is easier to administer, giving doctors ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects. The fibrin-specific plasminogen activator ...

Tenecteplase (TNKase) is the first new clot-busting drug to be approved in nearly 30 years, with the U.S. Food and Drug Administration (FDA) giving it the thumbs-up earlier this month. And now ...

(HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.